2 active not recruiting, 1 completed. 3 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Active not recruiting 2, Completed 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow INO-5401: new trials by email Literature Review of INO-5401 trials Research Report on INO-5401
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| INO 5401 Vaccination in BRCA1/2 Mutation Carriers INO-5401, INO-9012, Cellectra 2000 - BRCA1/2 Mutation | Phase 1 | Active not recruiting | University of Pennsylvania | 44 | 2021-04-20 | 2026-10-21 |
| INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma INO-5401, INO-9012, Atezolizumab - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 35 | 2018-07-24 | 2026-09-02 |
| INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) INO-5401, INO-9012, Cemiplimab - Glioblastoma | Phase 1 / Phase 2 | Active not recruiting | Inovio Pharmaceuticals | 52 | 2018-05-31 | 2026-10-22 |
Carcinoma, Transitional Cell (1) · Glioblastoma (1)
Inovio Pharmaceuticals (2) · University of Pennsylvania (1)
United States (3)
Jeffrey Skolnik, MD (2) · Susan Domchek, MD (1)